ProMetic Life Sciences (TSE:PLI) target price raised to $4.50, reported today by TD Securities
- Updated: September 28, 2016
ProMetic Life Sciences (TSE:PLI) had its target price raised to $4.50 by TD Securities in a report released 9/28/2016. The new target price indicates a possible upside of 0.53% based on the company's last stock close price.
Previously on 08/16/2016, Scotia Capital reported about ProMetic Life Sciences (TSE:PLI) raised the target price from $0.00 to $5.00. At the time, this indicated a possible upside of 0.81%.
Yesterday ProMetic Life Sciences (TSE:PLI) traded -0.67% lower at $2.95. The company’s 50-day moving average is $2.89 and its 200-day moving average is $3.02. The last stock close price is down -2.37% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 297,281 shares of the stock were exchanged, down from an average trading volume of 923,213
See Chart Below
ProMetic Life Sciences has a 52 week low of $1.43 and a 52 week high of $3.62 The company’s market cap is currently $0.
In addition to TD Securities reporting its target price, a total of 10 firms have reported on the stock. The consensus target price is $4.00 with 2 firms rating the stock a strong buy, 7 firms rating the stock a buy, 1 firm rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About ProMetic Life Sciences (TSE:PLI)
ProMetic Life Sciences Inc. (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also developing its own small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. It has research and development facilities in the United Kingdom, the United States and Canada; manufacturing facilities in the Isle of Man and Canada, and business development activities in the United States, Europe and Asia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.